We are live on ! Find out more
MYGN icon

Myriad Genetics

196 hedge funds and large institutions have $828M invested in Myriad Genetics in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

30% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 57

25% more call options, than puts

Call options by funds: $3.12M | Put options by funds: $2.5M

3% more funds holding

Funds holding: 190196 (+6)

1% less ownership

Funds ownership: 98.96%97.95% (-1%)

22% less capital invested

Capital invested by funds: $1.06B → $828M (-$228M)

Holders
196
Holders Change
+6
Holders Change %
+3.16%
% of All Funds
4.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
30
Increased
74
Reduced
57
Closed
22
Calls
$3.12M
Puts
$2.5M
Net Calls
+$618K
Net Calls Change
+$3.61M
Name Holding Trade Value Shares
Change
Change in
Stake
Ensign Peak Advisors
76
Ensign Peak Advisors
Utah
$712K
Fisher Asset Management
77
Fisher Asset Management
Washington
$700K +$525 +37 +0.1%
Deutsche Bank
78
Deutsche Bank
Germany
$681K -$3.03M -213,614 -78%
TPSF
79
Texas Permanent School Fund
Texas
$668K -$63K -4,438 -7%
T. Rowe Price Associates
80
T. Rowe Price Associates
Maryland
$637K +$9.1K +641 +1%
SO
81
STRS Ohio
Ohio
$629K +$240K +16,900 +44%
Susquehanna International Group
82
Susquehanna International Group
Pennsylvania
$610K -$291K -20,467 -28%
Rafferty Asset Management
83
Rafferty Asset Management
New York
$601K +$610K +42,940 +425%
Renaissance Technologies
84
Renaissance Technologies
New York
$590K +$738K +52,000 New
Mirae Asset Global Investments
85
Mirae Asset Global Investments
South Korea
$589K +$737K +51,868 New
AIG
86
American International Group
New York
$575K +$20.5K +1,442 +3%
OAM
87
Oppenheimer Asset Management
New York
$549K -$18.2K -1,279 -3%
Capital Fund Management (CFM)
88
Capital Fund Management (CFM)
France
$536K +$672K +47,292 New
BBHC
89
Brown Brothers Harriman & Co
New York
$535K
State of Tennessee, Department of Treasury
90
State of Tennessee, Department of Treasury
Tennessee
$499K -$46.4K -3,267 -7%
Millennium Management
91
Millennium Management
New York
$486K -$198K -13,944 -25%
AIA
92
AIMZ Investment Advisors
California
$484K -$2.84K -200 -0.5%
Manulife (Manufacturers Life Insurance)
93
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$472K -$34.5K -2,433 -5%
Jane Street
94
Jane Street
New York
$471K +$591K +41,595 New
State Board of Administration of Florida Retirement System
95
State Board of Administration of Florida Retirement System
Florida
$441K
VOYA Investment Management
96
VOYA Investment Management
Georgia
$435K -$148K -10,422 -21%
KBC Group
97
KBC Group
Belgium
$426K -$85K -5,986 -14%
COPPSERS
98
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$426K +$1.45K +102 +0.3%
ECM
99
ExodusPoint Capital Management
New York
$418K +$523K +36,839 New
VRS
100
Virginia Retirement Systems
Virginia
$412K -$116K -8,200 -18%

MYGN Hedge Fund Activity: Q2 2020 in Review

196 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2020, worth a combined $828M — down 22% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new MYGN positions and 22 closed out — a net gain of 8 holders — while 74 added to existing stakes and 57 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $23.4M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $128M sold.

  • 196 institutional investors held Myriad Genetics (MYGN) as of Q2 2020, up from 190 in Q1 2020.
  • Funds reported $828M of Myriad Genetics stock for Q2 2020, down 22% quarter-over-quarter.
  • 30 funds opened new Myriad Genetics positions in Q2 2020 and 22 closed out, a net change of +8 holders.
  • The largest Myriad Genetics buyer in Q2 2020 was Camber Capital Management, an estimated $23.4M added.
  • The largest Myriad Genetics seller in Q2 2020 was Baillie Gifford & Co, an estimated $128M sold.

Based on aggregated 13F filings for Q2 2020.